Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway

BACKGROUND: Cisplatin is one of the first-line drugs for urothelial bladder cancer (UBC) treatment. However, its considerable side effects and the emergence of drug resistance are becoming major limitations for its application. This study aimed to investigate whether matrine and cisplatin could pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xiao-Zhong, Tao, Lan-Ting, Liu, Jia-Hui, Gu, Yue-Yu, Xie, Jun, Chen, Yuling, Lin, Mei-Gui, Liu, Tao-Li, Wang, Dong-Mei, Guo, Hai-Yan, Mo, Sui-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745706/
https://www.ncbi.nlm.nih.gov/pubmed/29299027
http://dx.doi.org/10.1186/s12935-017-0495-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745706/
https://www.ncbi.nlm.nih.gov/pubmed/29299027
http://dx.doi.org/10.1186/s12935-017-0495-6

Ejemplares similares